CHCWM – Cancer & Hematology Centers of West Michigan

R6569-ONC-1933 (Regeneron)

A Phase 1 Study of REGN6569, an Anti-GITR mAb, with Cemiplimab in Patients with Advanced Solid Tumor Malignancies.